Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

Josep Tabernero, Sant P. Chawla, Hedy Kindler, Karen Reckamp, E. Gabriela Chiorean, Nilofer S. Azad, A. Craig Lockhart, Cheng Pang Hsu, Nigel F. Baker, Francesco Galimi, Pedro Beltran, José Baselga

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab'. Together they form a unique fingerprint.

Medicine & Life Sciences